Comparison of the efficacy of taxanes with carboplatin and anthracyclines with taxanes in neoadjuvant chemotherapy for stage II-III triple negative breast cancer: a retrospective analysis.
Huibo WangNana ZhangQi SunZiqi ZhaoHui PangXiatian HuangRuifeng ZhangWenli KangMing ShanPublished in: Journal of cancer research and clinical oncology (2024)
In stage II-III triple TNBC patients, the NACT regimen combining taxanes and carboplatin yields higher rates of pCR and significant improvements in EFS and OS as compared to the regimen combining anthracyclines and taxanes.
Keyphrases
- neoadjuvant chemotherapy
- end stage renal disease
- locally advanced
- phase ii study
- ejection fraction
- newly diagnosed
- chronic kidney disease
- lymph node
- sentinel lymph node
- peritoneal dialysis
- randomized controlled trial
- prognostic factors
- squamous cell carcinoma
- early breast cancer
- early stage
- patient reported outcomes
- phase iii
- rectal cancer